Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency.
Growth hormone insensitivity syndrome (GHI) or insulin-like growth factor-1 (IGF-1) deficiency (IGFD) is characterized by deficit of IGF-1 production due to alteration of response of growth hormone (GH) receptor to GH. This syndrome is due to mutation of GH receptor or IGF-1 gene and patients affected showed no response to GH therapy. The only treatment is recombinant IGF-1 (mecasermin), which has been available since 1986, but approved in the United States by the US Food and Drug Administration only in 2005 and in Europe by the European Medicines Agency in 2007. To date, few studies are available on long-term treatment with mecasermin in IGFD patients and some of them have a very small number of subjects. In this review we discuss briefly clinical features of severe primary IGFD, laboratory findings, and indications for treatment. Results of long-term therapy with rhIGF1 (mecasermin) in patients affected by severe primary IGFD and possible side effects are explained.
Fintini
Danilo
D
Endocrinology Unit, "Bambino Gesù" Children's Hospital-IRCCS, Rome, Italy.
Brufani
Claudia
C
Cappa
Marco
M
Horm Res. 2006;65 Suppl 1:15-20
16508329
J Clin Endocrinol Metab. 2001 Nov;86(11):5176-83
11701674
Clin Endocrinol (Oxf). 2004 Feb;60(2):163-8; discussion 161-2
14725676
J Pediatr. 2007 Jan;150(1):7-11
17188604
N Engl J Med. 1987 Jul 16;317(3):137-40
3299085
Curr Opin Investig Drugs. 2006 Apr;7(4):371-80
16625824
J Clin Endocrinol Metab. 2004 Mar;89(3):1031-44
15001582
Adv Ther. 2009 Jan;26(1):40-54
19198769
Growth Horm IGF Res. 2006 Oct-Dec;16(5-6):277-89
17101287
J Clin Endocrinol Metab. 2001 Apr;86(4):1504-10
11297575
Horm Res. 2003;60(5):237-46
14614229
Eur J Pediatr. 1980 Jun;134(1):79-83
7408914
J Clin Endocrinol Metab. 2007 Mar;92(3):902-10
17192294
J Clin Endocrinol Metab. 1995 Apr;80(4):1393-8
7536209
J Bone Miner Res. 1998 Mar;13(3):415-21
9525342
Acta Paediatr Suppl. 1994 Apr;399:137-9
7949599
Endocr Rev. 2007 Feb;28(1):20-47
16931767
Horm Res. 1999;51(3):128-34
10461018
J Clin Endocrinol Metab. 2008 Jan;93(1):10-8
18165284
Endocr Dev. 2009;14:135-42
19293580
Clin Biochem. 2005 Jul;38(7):659-66
15885685
Metabolism. 1995 Oct;44(10 Suppl 4):113-8
7476303
Nat Clin Pract Endocrinol Metab. 2006 Jul;2(7):395-407
16932322
Isr J Med Sci. 1988 Feb;24(2):75-9
3356536
Curr Opin Pediatr. 2007 Aug;19(4):458-64
17630612
Trends Endocrinol Metab. 2007 May-Jun;18(4):134-41
17391978
Endocr Dev. 2005;9:100-106
15879692
J Pediatr Endocrinol Metab. 2003 Apr-May;16(4):509-20
12793602
J Clin Endocrinol Metab. 1999 Dec;84(12):4436-43
10599699
Endocr Rev. 2001 Feb;22(1):53-74
11159816
Lancet. 1992 May 23;339(8804):1258-61
1349669
J Clin Endocrinol Metab. 2004 May;89(5):2271-4
15126552
J Endocrinol Invest. 2007 May;30(5):417-20
17598975
J Clin Endocrinol Metab. 1997 Feb;82(2):629-33
9024266
N Engl J Med. 1996 Oct 31;335(18):1363-7
8857020
J Clin Endocrinol Metab. 2006 Apr;91(4):1246-53
16403822
Acta Paediatr Suppl. 1994 Apr;399:112-4
7949594
J Pediatr Endocrinol Metab. 1999 Apr;12 Suppl 1:231-49
10698588
J Clin Endocrinol Metab. 2003 Oct;88(10):4586-9
14557426
N Engl J Med. 2004 Feb 5;350(6):570-7
14762184
J Clin Endocrinol Metab. 1993 Jul;77(1):273-80
7686916